Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Taipei Medical University WanFang Hospital57 enrolled

Overview

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. The strongest fucoidan among all seaweed for inhibiting cancer cells is in Okinawa Japanese waters. For chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. However, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell. Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Enrollment

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

275mg Oligo Fucoidan + 275mg HS FucoxanthinOTHER

Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

placebo pillsOTHER

taking placebo pills as if patients are under treatment.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD). Exclusion Criteria: 1. Patients were allergic to seafood. 2. Patients who take Vitamin E or Pioglitazone.

Locations (1)

WanFangH

Taipei, Taiwan

Outcomes

Primary Outcomes

Change in ALT Index

Measure the first month and the sixth-month change in the index which is ALT related to Liver inflammation.

Time frame: 6 months

Change in AST Index

Measure the first month and the sixth-month change in the index which is AST relate to Liver inflammation

Time frame: 6 months

Change in HbA1c

Measure the first month and the sixth-month change in the index which is HbA1c relate to Liver inflammation

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.